Clinical trials of revascularization therapy in diabetics

Current Opinion in Cardiology

Volumn 15, Issue 4, 2000, Pages 287-292

  Brooks, Robert C ^a   Detre, Katherine M ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; INTERNAL MAMMARY ARTERY; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 0033916115     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200007000-00014     Document Type: Review

References (29)

1. 1 Stamler J, Vaccaro O, Neaton JD, et al.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
2. 2 Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
3. 3 Abbott RD, Donahue RP, Kannel WB, et al.: The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 1988, 260:3456-3460.
4. 4 Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction: The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21:69-75.
5. 5 Morris JJ, Smith LR, Jones RH, et al.: Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991, 84 (suppl III):275-284.
6. 6 Alderman EL, Corley SD, Fisher LD, et al.: Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993, 22:1141-1154.
7. 7 Thourani VH, Weintraub WS, Stein B, et al.: Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999, 67:1045-1052.
8. 8 Kip KE, Faxon DP, Detre KM, et al., for the Investigators of the NHLBI PTCA Registry: Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996, 94:1818-1825.
9. 9 Stein B, Weintraub WS, Gebhart SSP, et al.: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995, 91:979-989.
10. 10 Carrozza JP, Kuntz KE, Fishman RF, et al.: Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993, 118:344-349.
11. 11 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996, 335:217-225.
12. 12 The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997, 96:1761-1769.
13. 13 BARI Investigators. Seven year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000, 35:1122-1129. Long-term follow up in the largest trial of patients with multivessel disease randomized to CABG versus PTCA showed a significant overall survival benefit for CABG at 7 years (84.4 vs 80.9%, P = 0.043). This benefit was entirely attributable to improved survival in diabetic patients (76.4 with CABG vs 55.7% with PTCA, P = 0.0011), with no difference in survival among patients without treated diabetes.
14. 14 Detre KM, Guo P, Holubkov R, et al.: Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999, 99:633-640.
15. 15 Chaitman BR, Rosen AD, Williams DO, et al. on behalf on the BARI Investigators: Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation 1997, 96:2162-2170.
16. 16 Detre KM, Lombardero MS, Brooks MM, et al.: The effect of bypass surgery on the prognosis of myocardial infarction in diabetic patients. N Engl J Med 2000, 342:989-997. This study suggests that the survival benefit seen with CABG in diabetic patients may be significantly related to an improvement in subsequent mortality with myocardial infarction. Among patients with multivessel disease eligible for the BARI trial, diabetic patients had significantly higher rates of death and spontaneous Q-wave MI at 5 years compared with non-diabetic patients. Previous CABG (as initial revascularization or subsequent procedure) dramatically reduced the high mortality after spontaneous Q-wave myocardial infarction in diabetic patients (relative risk 0.09, P< .001) but not in non-diabetic patients (P = .26). A smaller protective effect of CABG on mortality was also seen in diabetic patients who did not have spontaneous Q-wave myocardial infarction (relative risk 0.65).
17. 17 King SB, Lembo NJ, Weintraub WS, et al., for the Emory Angioplasty Versus Surgery Trial (EAST): A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 1994, 331:1044-1050.
18. 18 King SB, Kosinski AS, Guyton RA, et al., for the Emory Angioplasty versus Surgery Trial (EAST) Investigators: Eight year mortality in the Emory Angioplasty vs. Surgery Trial (EAST). J Am Coll Cardiol 2000, 35:1116-1121. Long-term follow-up evaluation in this randomized trial of CABG versus PTCA in patients with multivessel disease showed no mortality difference in the overall study population, but diabetic patients demonstrated a trend toward improved late survival with surgical intervention (75.5 vs 60.1%, P = 0.23).
19. 19 CABRI Trial Participants: First-year results of CABRI (Coronary Artery versus Bypass Revascularization Investigation). Lancet 1995, 346:1179-1184.
20. 20 Bertran M.: Long-term follow-up of European revascularization trials. Presented at the 68th Scientific Sessions, Plenary Session XII, of the American Heart Association. Anaheim, Calif, November 16, 1995.
21. 21 Henderson RA, Pocock SJ, Sharp SJ, et al., for the Randomised Intervention Treatment of Angina (RITA-1) trial participants: Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Lancet 1998, 352:1419-1425.
22. 22 Detre KM, Rosen AD, Bost JE, et al.: Contemporary practice of coronary revascularization in US hospitals and hospitals participating in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1996, 28:609-615.
23. 23 Detre KM, Peduzzi P, Takaro T, et al.: Eleven-year survival in the Veterans Administration Randomized Trial of Coronary Bypass Surgery for Stable Angina. N Engl J Med 1984, 311:1333-1339.
24. 24 CASS Principal Investigators and their Associates: Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983, 68:939-950.
25. 25 Varnauskas E.: Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. New Engl J Med 1988, 319:332-337.
26. 26 RITA-2 Participants: Coronary angioplasty versus medical treatment for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997, 350:461-468.
27. 27 Davies RF, Goldberg AD, Forman S, et al.: Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997, 95:2037-2043.
28. 28 Gibbons RJ, Chatterjee K, Daley J, et al.: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol 1999, 33:2092-2197.
29. 29 Pitt B, Waters D, Brown WB, et al.: for the Atorvastatin Versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999, 341:70-76.